Clinical outcomes in non‐small‐cell lung cancer patients with EGFR mutations: pooled analysis
L Paz‐Ares, D Soulières, I Melezínek… - Journal of cellular …, 2010 - Wiley Online Library
Introduction• Literature review‐Molecular biology of EGFR mutations‐Clinical characteristics
of NSCLC patients with EGFR mutations‐Genetic characteristics of EGFR‐mutated tumours …
of NSCLC patients with EGFR mutations‐Genetic characteristics of EGFR‐mutated tumours …
Epidermal growth factor receptor tyrosine kinase inhibitors as first-line treatment in advanced nonsmall-cell lung cancer
R Rosell, S Viteri, MA Molina, S Benlloch… - Current opinion in …, 2010 - journals.lww.com
Nonsmall-cell lung cancer with EGFR mutations constitute a new entity with a unique
opportunity for further refinement of different genetic subgroups among patients with EGFR …
opportunity for further refinement of different genetic subgroups among patients with EGFR …
Third generation EGFR TKIs in EGFR-mutated NSCLC: where are we now and where are we going
A Russo, T Franchina, GRR Ricciardi… - Critical reviews in …, 2017 - Elsevier
The therapeutic landscape of Non Small Lung Cancer (NSCLC) has been profoundly
changed over the last decade with the clinical introduction of Epidermal Growth Factor …
changed over the last decade with the clinical introduction of Epidermal Growth Factor …
Intrinsic Resistance to EGFR-Tyrosine Kinase Inhibitors in EGFR-Mutant Non-Small Cell Lung Cancer: Differences and Similarities with Acquired Resistance
E Santoni-Rugiu, LC Melchior, EM Urbanska… - Cancers, 2019 - mdpi.com
Activating mutations in the epidermal growth factor receptor gene occur as early cancer-
driving clonal events in a subset of patients with non-small cell lung cancer (NSCLC) and …
driving clonal events in a subset of patients with non-small cell lung cancer (NSCLC) and …
Epidermal growth factor receptor tyrosine kinase inhibitors: current status and future perspectives in the development of novel irreversible inhibitors for the treatment of …
E Galvani, R Alfieri, E Giovannetti… - Current …, 2013 - ingentaconnect.com
Conventional chemotherapeutic regimens have reached an efficacy plateau against most
solid tumors and deal with significant toxicity. Recently, the goal of oncologic research to …
solid tumors and deal with significant toxicity. Recently, the goal of oncologic research to …
The presence of concomitant mutations affects the activity of EGFR tyrosine kinase inhibitors in EGFR-mutant non-small cell lung cancer (NSCLC) patients
AM Rachiglio, F Fenizia, MC Piccirillo, D Galetta… - Cancers, 2019 - mdpi.com
Recent findings suggest that a fraction of EGFR-mutant non-small-cell lung cancers
(NSCLC) carry additional driver mutations that could potentially affect the activity of EGFR …
(NSCLC) carry additional driver mutations that could potentially affect the activity of EGFR …
Management of acquired resistance to EGFR TKI–targeted therapy in advanced non-small cell lung cancer
SG Wu, JY Shih - Molecular cancer, 2018 - Springer
Recent advances in diagnosis and treatment are enabling a more targeted approach to
treating lung cancers. Therapy targeting the specific oncogenic driver mutation could inhibit …
treating lung cancers. Therapy targeting the specific oncogenic driver mutation could inhibit …
Drug resistance of targeted therapy for advanced non-small cell lung cancer harbored EGFR mutation: From mechanism analysis to clinical strategy
Y Zhao, H Wang, C He - Journal of Cancer Research and Clinical …, 2021 - Springer
Purpose Non-small cell lung cancer (NSCLC) accounts for about 85% in all cases of lung
cancer. In recent years, molecular targeting drugs for NSCLC have been developed rapidly …
cancer. In recent years, molecular targeting drugs for NSCLC have been developed rapidly …
Treatment strategies for non-small cell lung cancer harboring common and uncommon EGFR mutations: drug sensitivity based on exon classification, and structure …
R Kitadai, Y Okuma - Cancers, 2022 - mdpi.com
Simple Summary The advent of epidermal growth factor receptor (EGFR) tyrosine kinase
inhibitors (EGFR-TKIs) has led to a dramatic improvement in the prognosis of patients …
inhibitors (EGFR-TKIs) has led to a dramatic improvement in the prognosis of patients …
[HTML][HTML] Mechanisms of resistance to EGFR-targeted drugs: lung cancer
F Morgillo, CM Della Corte, M Fasano, F Ciardiello - ESMO open, 2016 - Elsevier
Despite the improvement in clinical outcomes derived by the introduction of epidermal
growth factor receptor (EGFR) tyrosine kinase inhibitors (EGFR-TKIs) in the treatment of …
growth factor receptor (EGFR) tyrosine kinase inhibitors (EGFR-TKIs) in the treatment of …